Jupiter Neurosciences (JUNS) risk factors, FY2025 10-K

Other

1. 01Our substantial amount of indebtedness may adversely affect our cash flow and our ability to operate our business, remain in compliance with debt covenants and make payments on our indebtedness100% rewritten

Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History

1. 02We are early in our development efforts, with a limited operating history, and we have no prescription products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and future viability43% rewritten
2. 03We have not generated any meaningful revenue from product sales to date, have incurred significant net losses since our inception, and expect to continue to incur significant net losses for the foreseeable future47% rewritten
3. 04Our management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal years ended December 31, 2025 and 2024
4. 05Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the discovery, development and commercialization of our product candidates, if approved74% rewritten
5. 06We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts68% rewritten
6. 07Raising additional capital may cause substantial dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
7. 08The actual number of shares of common stock we will issue pursuant to the SEPA, if not terminated and if and when available, at any one time or in total, is uncertainNew
8. 09Low trading volume in our common stock may limit or prevent our ability to draw on the Standby Equity Purchase AgreementNew
9. 10Any of the above listed factors could materially adversely affect our business, financial condition and results of operations
10. 11Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited
11. 12Changes in U.S. tax laws and regulations and those which we are subject to in various tax jurisdictions could adversely affect our business, financial condition and results of operationsNew
12. 13Any shares of common stock we issue under the SEPA, if not terminated and if and when available, will further dilute our stockholdersNew

Risks Related to the Launch of the Nugevia Brand

1. 14If the Company or its suppliers fails to comply with FDA or other regulations, it could result in enforcement actions or delays in the Nugevia brand product launchNew
2. 15The global nutraceutical market is highly competitive, with many brands offering products that are similar to Nugevia. Failure to differentiate from competitors could limit market penetration and revenue potentialNew
3. 16The Company is dependent on certain proprietary supply-chain vulnerabilities with operational and supply chain risksNew
4. 17If there are intellectual property disputes relating to the JOTROL™ technology, it could threaten Nugevia’s market positionNew

Risks Related to the Discovery, Development and Commercialization of Our Product Candidate

1. 18In addition to JOTROL™, our prospects depend in part upon discovering, developing and commercializing product candidates in future programs, which may fail or suffer delays that adversely affect their commercial viability
2. 19The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities
3. 20If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented
4. 21We have limited resources and are currently focusing the majority of our efforts on developing JOTROL™ for particular indications. As a result, we may fail to capitalize on other indications or product candidates that may ultimately have proven to be more profitable
5. 22We face significant competition and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the products we develop, our commercial opportunities will be negatively impacted
6. 23Interim, topline and preliminary data from our clinical trials that we announce or publish may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
7. 24We may not be successful in our efforts to develop our proprietary drug delivery platform, JOTROL™, to build a pipeline of indications
8. 25We may develop JOTROL™ and potentially other programs in combination with other therapies, which would expose us to additional risks
9. 26Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success
10. 27If any of our product candidates are approved but do not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively impacted
11. 28Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations

Risks Related to Regulatory Approval and Other Legal Compliance Matters

1. 29The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction
2. 30Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
3. 31The regulatory approval processes for any product candidates that target rare diseases, including MPS I and MELAS are uncertain
4. 32Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight27% rewritten
5. 33We may not be able to obtain orphan drug designation or obtain or maintain orphan drug exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA, EMA or other comparable foreign regulatory authorities, from approving competing products27% rewritten
6. 34If our Nugevia nutritional supplement products do not have the effects intended or cause undesirable side effects, our business may sufferNew
7. 35Our competitors may develop nutritional supplement products that are less expensive, safer or otherwise more appealing, which may diminish or eliminate the commercial success of any potential product that we may commercializeNew
8. 36Our Nugevia products are subject to regulatory requirements and failure to comply with any regulations could lead to significant penalties or claims, which could materially harm our financial condition and operating resultsNew
9. 37We may face difficulties from changes to current regulations and future legislation71% rewritten

Risks Related to Data Privacy and Security

1. 38We are subject to an evolving array of U.S. and foreign privacy, and data protection, and data security laws regulations, and standards, and any failure or perceived failure to comply could result in regulatory investigations, litigation, significant fines and penalties, operational restrictions, and reputational harmNew
2. 39Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
3. 40I f we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business

Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business

1. 41Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees
2. 42If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval
3. 43In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth68% rewritten

Risks Related to Cybersecurity and Information Technology Disruptions

1. 44Our information technology systems and those of any of our CROs, clinical sites, manufacturers, vendors, and other partners are subject to cybersecurity threats and other disruptions that could adversely affect our operations and the development and commercialization of our product candidatesNew
2. 45Our employees and executives may use artificial intelligence tools in ways that expose our confidential information, intellectual property, or clinical data to third parties, and the evolving regulatory and legal landscape around artificial intelligence could adversely affect our businessNew
3. 46Our operations are vulnerable to interruption by fire, earthquakes, power loss, telecommunications failure, terrorist activity, pandemics and other events beyond our control, which could harm our business
4. 47A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business93% rewritten
5. 48By purchasing our common stock, you are bound by the fee-shifting provision contained in our amended and restated bylaws, which may discourage you to pursue actions against us and could discourage stockholder lawsuits that might otherwise benefit the Company and its stockholders
6. 49We adopted the fee-shifting provision to eliminate or decrease nuisance and frivolous litigation. We intend to apply the fee-shifting provision broadly to all actions except for claims brought under the Exchange Act and Securities Act

Risks Related to Our Intellectual Property

1. 50Our worldwide exclusive license agreement with Aquanova for JOTROL™ is critical to our business. If we were to lose the license agreement, it could disrupt our ability to commercialize our Nugevia product line or pharmaceutical drug candidatesNew
2. 51Our success depends on our ability to protect our intellectual property and our proprietary technologies53% rewritten
3. 52If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected
4. 53Intellectual property rights do not necessarily address all potential threats to our competitive advantage99% rewritten
5. 54Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts
6. 55We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses
7. 56We may be involved in lawsuits to protect or enforce our patents or our licensor’s patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents or our licensor’s patents could be found invalid or unenforceable if challenged in court
8. 57In addition, if the breadth or strength of protection provided by our patents and patent applications or the patents and patent applications of our licensor is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates
9. 58Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common stock to decline
10. 59Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party
11. 60Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
12. 61We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
13. 62Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
14. 63If we do not obtain patent term extension for our product candidates, our business may be materially harmed
15. 64We may not be able to protect our intellectual property rights throughout the world
16. 65Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
17. 66If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
18. 67If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed99% rewritten
19. 68We may be subject to claims that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets99% rewritten
20. 69We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers
21. 70Our rights to develop and commercialize our technology and product candidates may be subject, in part, to the terms and conditions of licenses granted to us by others
22. 71If we fail to comply with our obligations in the agreements under which we license intellectual property rights from Aquanova or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business100% rewritten
23. 72The patent protection and patent prosecution for some of our product candidates may be dependent on third parties

Risks Related to Our Dependence on Third Parties

1. 73We rely, and expect to continue to rely, on third parties to conduct our clinical trials and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies, which may harm our business97% rewritten
2. 74We may rely on third-party manufacturers and distributors for our Nugevia product line, and any failure by these third parties to perform could adversely affect our businessNew
3. 75Our reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
4. 76If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks85% rewritten
5. 77If we decide to establish collaborations, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans100% rewritten
6. 78We may enter into collaborations with third parties for the development and commercialization of product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates99% rewritten
7. 79Even if we are able to commercialize our product candidates, the products may not receive coverage and adequate reimbursement from third-party payers, which could harm our businessNew

Risks Related to Ownership of Our Securities

1. 80The Company’s failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of its securities85% rewritten
2. 81If Nasdaq delists the Company’s common stock, the Company’s liquidity and market price could be affectedNew
3. 82The price of our common stock could be subject to rapid and substantial volatility
4. 83A “short squeeze” due to a sudden increase in demand for shares of our common stock could lead to extreme price volatility in shares of our common stock New
5. 84The market price of our common stock may be volatile, and you could lose all or part of your investment95% rewritten
6. 85If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline
7. 86Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance100% rewritten
8. 87Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval23% rewritten
9. 88If the benefits of any proposed acquisition do not meet the expectations of investors, stockholders or financial analysts, the market price of our Common Stock may decline
10. 89Changes in accounting principles and guidance, or their interpretation, could result in unfavorable accounting charges or effects, including changes to our previously filed financial statements, which could cause our stock price to decline
11. 90As an “emerging growth company” under the JOBS Act, we are permitted to rely on exemptions from certain disclosure requirements87% rewritten
12. 91If we are unable to maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and have an adverse effect on the value of our securities
13. 92As an emerging growth company, our auditor will not be required to attest to the effectiveness of our internal controls
14. 93We believe we will be considered a smaller reporting company and will be exempt from certain disclosure requirements, which could make our Common Stock less attractive to potential investors93% rewritten
15. 94We incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives98% rewritten
16. 95Shares eligible for future sale may adversely affect the market
17. 96Anti-takeover provisions contained in our certificate of incorporation, as amended, and amended and restated bylaws, as well as provisions of Delaware law, could impair a takeover attempt100% rewritten
18. 97We may be subject to securities litigation, which is expensive and could divert management attention
19. 98We have never paid dividends on our common stock and have no plans to do so in the future
20. 99We will indemnify and hold harmless our officers and directors to the maximum extent permitted by Delaware law